Evidence. Status. Comparisons. Sources.

Understand any peptide.

24 peptide evidence records51 inspectable sources129 reviewed answers

HOW EVIDENCE IS GRADED

Two evidence lines. One shared scale.

Read the methodology
01

Human evidence

Clinical findings, populations, outcomes, and study maturity.

02

Preclinical evidence

Cell, animal, mechanism, and translational research—kept separate.

1/5 · Very limited
2/5 · Early
3/5 · Developing
4/5 · Substantial
5/5 · Mature

Bars describe evidence depth—not effectiveness, safety, product quality, or personal suitability.

WHAT CHANGED

Freshness should be inspectable.

New source events and record revisions keep their dates, primary sources, and evidence boundaries visible.

NEWS & ANALYSIS

FDA revises its playbook for generic peptide products

Seventeen revised draft product-specific guidances explain the evidence FDA expects for certain generic peptide applications.

Retatrutide clears two more Phase 3 readouts—but remains investigational

Lilly reported positive topline TRIUMPH-2 and TRIUMPH-3 results. The data are important, but they are not an FDA approval.

FDA clarifies compounded GLP-1 policy after supply stabilizes

The agency restated the legal boundary between limited compounding exceptions and routine copies of approved GLP-1 medicines.

RECENT RECORD UPDATES

Evidence matrix 2026.08.08 released

Added stable source IDs and original URLs to the matrix export, plus a normalized source-library export.

Source library published

Added first-class provenance pages connecting each cited source to every peptide evidence record that uses it.

Epitalon and DSIP enforcement link corrected

Replaced a retired FDA mirror URL with the live U.S. Department of Justice record and corrected the publisher classification.